Stock Market logoStock Market Station

All the stock market news, every minute updated!

17 September 2021
22:20 hour

Syneos Health acquires clinical trial recruitment company StudyKIK

Seeking Alpha

14/09/2021 - 23:46


READ THE FULL ARTICLE ON SEEKING ALPHA

Related headlines:

  1. Syneos Health partners with Ride Health to improve clinical trial recruitment (09/09/2021 - Seeking Alpha)

    [visit article]
  2. Covid-19: Five pharma companies collaborate for clinical trial of oral anti-viral drug Molnupiravir (29/06/2021 - Financial Express)
    Following the clinical trial protocol approval given by the Drugs Controller General of India, the clinical trial is expected to take place between June and September.
    [visit article]
  3. Thermo Fisher ($TMO) to buy contract research organization PPD ($PPD), PPD stock rises 12.10% in last 10 min of trading on 4/14 (15/04/2021 - Reddit Stocks)
    https://www.bloomberg.com/news/articles/2021-04-15/thermo-fisher-to-buy-ppd-for-17-4-billion-as-health-deals-soar "Thermo Fisher Scientific Inc. has agreed to acquire PPD Inc. a provider of clinical and research services to the pharma and biotech industries, for $17.4 billion as health-care dealmaking soars amid the pandemic. Thermo Fisher will pay $47.50 a share for PPD, according to a statement Thursday, and will assume about $3.5 billion of debt. The price represents a premium of about 24% to the PPD closing price Tuesday, before reports of a possible deal." PPD has been trading in the $33-38 range for nearly a year now, just shot up to $43 EOD. Thermo is a massive company for life sciences equipment and reagents. PPD is a CRO, a company that does clinical trial work (clinical coordination, laboratory testing of clinical trial samples, etc.) for other companies' drug, vaccine etc. development pipelines. Will be interesting to see what prices of both these companies look like at open today.   submitted by   /u/carlyslayjedsen [link]   [comments]
    [visit article]
  4. Kochi firm PNB Vesper Life completes phase 2 clinical trial of Covid drug (22/02/2021 - Financial Express)
    The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients.
    [visit article]
  5. DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences (03/09/2021 - Financial Express)
    The firm is required to submit the revised clinical trial protocol for immunogenicity to be assessed on Day 42, instead of Day 14, as recommended by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation, a source said, citing the conditions set for the trial.
    [visit article]
  6. Balacovin: Kerala firm PNB Vesper Life gets nod for phase 3 clinical trial of Covid drug (25/06/2021 - Financial Express)
    The company will be conducting a nationwide multi-centred clinical trial of the drug- PNB-001 (GPP-BALACOVIN), on Covid-19 patients who are hospitalised and are on oxygen support.
    [visit article]
  7. Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list (01/05/2021 - Reddit Stock Market)
    Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ??(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects' information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial. Today, FINRA processed a Form 211 relating to the initiation of priced quotations of HMTXF on OTCQB, where the Company has reapplied to be listed. The submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and has met the requirements under that rule to initiate quotation of HMTXF within three business days. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  8. Syneos Health Q4 2020 Earnings Preview (17/02/2021 - Seeking Alpha)

    [visit article]
  9. Syneos Health EPS beats by $0.01, misses on revenue (18/02/2021 - Seeking Alpha)

    [visit article]
  10. Syneos Health enters 7M secondary offering (01/03/2021 - Seeking Alpha)

    [visit article]
  11. Syneos Health Q2 2021 Earnings Preview (06/08/2021 - Seeking Alpha)

    [visit article]
  12. Syneos Health Q1 2021 Earnings Preview (28/04/2021 - Seeking Alpha)

    [visit article]
  13. Syneos Health, Skillz among premarket losers' pack (03/06/2021 - Seeking Alpha)

    [visit article]
  14. Syneos Health commences secondary offering of 10.85M shares (02/06/2021 - Seeking Alpha)

    [visit article]
  15. Syneos Health gains following Thermo Fisher $17B deal for PPD (15/04/2021 - Seeking Alpha)

    [visit article]
  16. Syneos Health commences 7M share secondary offering (03/05/2021 - Seeking Alpha)

    [visit article]
  17. Syneos Health names Michael Brooks chief development officer (14/07/2021 - Seeking Alpha)

    [visit article]
  18. AzurRx activates new clinical trial sites in India for mid-stage FW-1022 COVID-19 trial (10/09/2021 - Seeking Alpha)

    [visit article]
  19. Ascendis files clinical trial notification for late-stage TransCon PTH trial in japan (12/05/2021 - Seeking Alpha)

    [visit article]
  20. HCG acquires oncology hospital lab, clinical trials business from Strand Lifesciences (04/09/2021 - Money Works 4 Me)
    The company also divested its 38.5% stake in Strand to Reliance Industries group company
    [visit article]
  21. Coronavirus Update: CureVac’s vaccine disappoints in major trial, says it was poor match against 29 COVID variants (17/06/2021 - Market Watch)
    The global tally of confirmed cases of COVID-19 climbed above 177 million on Thursday, a day after disappointing news from CureVac with the German company saying its vaccine was only 47% effective in a late-stage clinical trial.
    [visit article]
  22. $WELL $WLYYF Completes Another Successful Acquisition! (03/05/2021 - Reddit Stocks)
    Well Health just announced they have acquired ExecHealth, marking their first clinical asset in the province of Ontario. I have been following this company since I saw Mr. Li Ka Shing invested $105M of $305M at a 25% premium to market. Since then they have made a number of impressive acquisitions and it looks like that is not stopping anytime soon! https://www.prnewswire.com/news-releases/wells-clinical-business-unit-expands-corporate-and-executive-health-services-with-completion-of-exechealth-acquisition-301282023.html   submitted by   /u/cheeselover556 [link]   [comments]
    [visit article]
  23. CRSPR company Caribou Biosciences (CRBU) recent IPO (27/07/2021 - Reddit Stocks)
    I did open a position in this stock and none of this is financial advice. A CRSPR company $CRBU Caribou Biosciences went IPO recently and is now around $16. Total market cap $835.73M. Jennifer Doudna and Martin Jinek, two people who did some of the most groundbreaking CRSPR research, are scientific advisors. The other CRSPR stocks (I bought all 3) are CRSP and NTLA both around $120, and EDIT which is ~$40. CRSP has cap 9.03B, NTLA, which is currently the leader and passed an early-stage clinical trial is 9.65B, and EDIT is 2.71B. CRSPR is going to be a big field in biopharma and medicine in the future, enough to sustain many more companies than the half dozen in the space right now. CRBU is currently in early clinical trials to treat non-hodgkins lymphoma. If they get favorable results (note: IN A YEAR OR TWO ONCE THE STUDY IS DONE) it is clear from the other CRSPR companies what kind of valuations these companies can reach. The Bear case is obviously the flipside. If their clinical trial is unsuccessful, while they do have other drugs in the pipeline as well, then their current valuation of $860M will be incredibly overvalues. Speculation play, but my MO is to just buy all the CRSPR stocks when it seems like a good entry point.   submitted by   /u/oarabbus [link]   [comments]
    [visit article]
  24. Valneva completes recruitment for late-stage inactivated COVID-19 vaccine trial (03/06/2021 - Seeking Alpha)

    [visit article]
  25. Optinose completes patient recruitment in pivotal trial for XHANCE in chronic sinusitis (30/07/2021 - Seeking Alpha)

    [visit article]
  26. $HEM.V Hemostemix Great pharmacy company! (11/03/2021 - Reddit Stock Market)
    Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. https://hemostemix.com/wp-content/uploads/2021/02/Corporate-Presentation-Investor-Jan-25-2021-v8.pdf https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/ https://investorintel.com/markets/biotech-healthcare/biotech-intel/fully-funded-with-strong-ip-portfolio-hemostemix-marches-forward-towards-fda-phase-ii-clinical-trial-completion/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958876/   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  27. TTK Healthcare eyes expansion for its medical devices business (21/08/2021 - Financial Express)
    The single centric clinical trial for the new model titanium valve would commence during the first half of the current year, according to the company.
    [visit article]
  28. Catalyst! Great potential! Hemostemix (12/05/2021 - Reddit Stock Market)
    Hemostemix ($HEM $HMTXF) Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis Hemostemix announced that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting documentation. This process is expected to take approximately three months. The Company has contracted a clinical data management services company to provide Hemostemix with clinical trial data base management services, including data base management plan adherence, data base edit checks, data base query management, data base integration and validation, data base reconciliations by events, data base analysis readiness reporting, data base hard lock, and data base closeout and delivery. Hemostemix is continuing with the data entry and source document verifications. As announced on April 23, the 65th (final) subject has completed their last follow-up visit and the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. Hemostemix filed on SEDAR its audited annual financial statements for the period ending December 31, 2020, with a comparison to the year earlier period, including the notes related thereto and also including the management discussion and analysis (MD&A). Disclaimer: this is not investment advice, please do your own DD.   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  29. Syneos Health EPS beats by $0.02, beats on revenue (09/08/2021 - Seeking Alpha)

    [visit article]
  30. Syneos Health EPS beats by $0.05, beats on revenue (29/04/2021 - Seeking Alpha)

    [visit article]
  31. Catalyst!???????? High potential, High risk! Big reward!!????????????Hemostemix???? (12/05/2021 - Reddit Stock Market)
    Hemostemix ($HEM $HMTXF) Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis Hemostemix announced that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting documentation. This process is expected to take approximately three months. The Company has contracted a clinical data management services company to provide Hemostemix with clinical trial data base management services, including data base management plan adherence, data base edit checks, data base query management, data base integration and validation, data base reconciliations by events, data base analysis readiness reporting, data base hard lock, and data base closeout and delivery. Hemostemix is continuing with the data entry and source document verifications. As announced on April 23, the 65th (final) subject has completed their last follow-up visit and the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. Hemostemix filed on SEDAR its audited annual financial statements for the period ending December 31, 2020, with a comparison to the year earlier period, including the notes related thereto and also including the management discussion and analysis (MD&A). Disclaimer: this is not investment advice, please do your own DD.   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  32. Covaxin phase 3 trial results out, Bharat Biotech says its Covid vaccine has 81% efficacy rate (03/03/2021 - Financial Express)
    As per the information provided by Bharat Biotech, the vaccine is up to 81 percent effective after its second dose in preventing the Coronavirus infection. The company also shared that the phase 3 clinical trials were conducted on a sample of 25,800 participants, which is the largest group of trial participants conducted in the country so far.
    [visit article]
  33. $HEM.V Great potential in 2021! loaded for blast!! (10/03/2021 - Reddit Stock Market)
    Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. https://hemostemix.com/wp-content/uploads/2021/02/Corporate-Presentation-Investor-Jan-25-2021-v8.pdf https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/ https://investorintel.com/markets/biotech-healthcare/biotech-intel/fully-funded-with-strong-ip-portfolio-hemostemix-marches-forward-towards-fda-phase-ii-clinical-trial-completion/   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  34. Bet on life. Bet on Surface Oncology (02/06/2021 - Reddit Stocks)
    Bet on life. Bet on surface oncology Why don’t we boost stocks that save people’s lives? AMC is great but imagine what we could do if we did the same for cancer companies. One I like is SURF A company with top management that barely dilutes but either raises money through loans or licensing their drugs. In late March the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to SF617, which is intended to treat pancreatic cancer. Surface owns the full rights to SF617, meaning that it will get the full benefits of the designation's package of additional allowances and intellectual property protections if the drug makes it through the clinical trial process. Collaboration with Merck. In the collaboration, Merck's first-line oncology drug, Keytruda, will be investigated in a phase 1 clinical trial in conjunction with Surface's SRF388. Liver cancer and kidney cancer are the intended targets, and investors will get an update on the program's progress in early June, at the American Society of Clinical Oncology's 2021 annual meeting. THIS FRIDAY!!!!! Financially, Surface is in good condition, though it has no recurring revenue as of yet. Its $175 million in cash is more than enough for it to continue with research and development (R&D) work through 2023. License with GSK and Novartis. IND’s coming up. Lots of milestones upcoming in clinical trials. SUB 500M for an immunotherapy company that has PROVEN the drug already works. Get in before this Friday it’s going to blow.   submitted by   /u/HaveADrinkOnMeCosby [link]   [comments]
    [visit article]
  35. $HEM.V Hemostemix Great pharmacy company! (19/03/2021 - Reddit Stock Market)
    Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. https://hemostemix.com/wp-content/uploads/2021/02/Corporate-Presentation-Investor-Jan-25-2021-v8.pdf https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/ https://investorintel.com/markets/biotech-healthcare/biotech-intel/fully-funded-with-strong-ip-portfolio-hemostemix-marches-forward-towards-fda-phase-ii-clinical-trial-completion/ https://stockhouse.com/opinion/interviews/2021/02/11/shaping-future-regenerative-medicine-today https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958876/   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  36. $HEM.V Hemostemix Great pharmacy company, big potential! (14/03/2021 - Reddit Stocks)
    Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. https://hemostemix.com/wp-content/uploads/2021/02/Corporate-Presentation-Investor-Jan-25-2021-v8.pdf https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/ https://investorintel.com/markets/biotech-healthcare/biotech-intel/fully-funded-with-strong-ip-portfolio-hemostemix-marches-forward-towards-fda-phase-ii-clinical-trial-completion/ https://stockhouse.com/opinion/interviews/2021/02/11/shaping-future-regenerative-medicine-today https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958876/   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  37. $HEM.V Hemostemix Great pharmacy company, Big potential! (14/03/2021 - Reddit Stock Market)
    Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, peripheral arterial disease, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia that is in Phase II clinical trial in Canada and the United States. It also offers various types of synergetic cell populations, such as angiogenic cell precursors, myocardial cell precursors, neural cell precursors, and bone cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. https://hemostemix.com/wp-content/uploads/2021/02/Corporate-Presentation-Investor-Jan-25-2021-v8.pdf https://investorintel.com/markets/biotech-healthcare/biotech-intel/hemostemix-steps-into-the-new-year-with-capital-and-its-critical-clinical-study-data-in-hand/ https://investorintel.com/markets/biotech-healthcare/biotech-intel/fully-funded-with-strong-ip-portfolio-hemostemix-marches-forward-towards-fda-phase-ii-clinical-trial-completion/ https://stockhouse.com/opinion/interviews/2021/02/11/shaping-future-regenerative-medicine-today https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958876/   submitted by   /u/DSPowerOfTheSun [link]   [comments]
    [visit article]
  38. MNMD IPO on NASDAQ tomorrow: Shrooms are the new Cannabis. (26/04/2021 - Reddit Stock Market)
    MNMD will IPO on the NASDAQ tomorrow: I like this stock since it looks like investing in Cannabis in 2011. Mushrooms are non-addictive. Several states are thinking about allowing it to be used in medical capacity. Oregon is the first state that has legislation in the works. I feel so bad for missing out on Cannabis gains but unlike Cannabis stocks that are all Canadian this will start with states legalizing mushroom for depression. The evidence for use of Mushrooms for clinical purposes is undeniable. Harm is low. Profits are great. Please see the following for further reading: A Study to Assess 18-Methoxycoronaridine https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine%2C+Inc.&lead_ex=Y&draw=2&rank=1 You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document. https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence. They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website: Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality. No IND required Fast-tracked approvals Generous R&D refunds Excellent health system Access to patient databases Data accepted by FDA, EMA, CFDA & PDMA Looks like to me they will fast track in Australia - then partner with J&J if successful. What you read on this post is my understanding of this company. Do not invest based on this post. ----------------------------------------------------- tl/dr: Shrooms are the next Cannabis and meme stock. IPO on NASDAQ tomorrow.   submitted by   /u/InvestingWithGusto [link]   [comments]
    [visit article]
  39. AZRX - One of very few "Long Covid" medications. 400% Upside to PT (04/06/2021 - Reddit Stocks)
    Hi. I don't often post about stocks but this one caught my eye and to me it looks like a steal, so I'm looking for other opinions. Headline: AZRX at time of writing is around 0.80 per share. The PTs are average of $4, so that's a 400% upside. Company aim: "AzurRx BioPharma (NASDAQ: AZRX) is a clinical stage biotechnology company currently focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, with two assets and three clinical indications." Trials: 2 trials regarding Exocrine Pancreatic Insufficiency in cystic fibrosis patients 1 trial for repurposing a drug to treat GI disease in COVID-19 patients 1 trial for Immune Checkpoint Inhibitor-Associated Colitis I'm not going to copy the spiel for the trials, the short of it is that they look promising, but you can read here https://www.azurrx.com/images/pdf/presentation/2021/June/AzurRx_Corporate_Presentation_June_2021_2021.6.1.pdf ​ Financials: 78M shares outstanding 2.08M short $3M of institutional holdings $0 debt $12M cash on hand ​ What are your thoughts? Could be squeeze potential and/or simply a good investment?   submitted by   /u/wayneio [link]   [comments]
    [visit article]
  40. Thoughts on clsn? (14/02/2021 - Reddit Stock Market)
    I have quite a few shares in CLSN because I think it has real potential. Info: “Celsion (CLSN) is a fully-integrated development stage oncology drug company focused on advancing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA based therapies. The company's lead product candidate is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Second in its pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers.” They just announced the formation a vaccine advisory board. https://finance.yahoo.com/news/celsion-corporation-announces-formation-vaccine-133000146.html What do you all think of this stock? I don’t really own any penny stocks besides this one. I really believe in it. I’m new to trade though, so hopefully I’m not being foolish with it.   submitted by   /u/johnswoed [link]   [comments]
    [visit article]
  41. MNMD IPO on NASDAQ tomorrow: Shrooms are the new Cannabis. (26/04/2021 - Reddit Stocks)
    MNMD will IPO on the NASDAQ tomorrow: I like this stock since it looks like investing in Cannabis in 2011. Mushrooms are none-addictive. States are thinking about allowing it to be used in medical capacity. Oregon is the first state that has legislation in the works. I feel so bad for missing out on Cannabis gains but unlike Cannabis stocks that are all Canadian this will start with states legalizing mushroom for depression. The evidence for use of Mushrooms for clinical purposes is undeniable. Harm is low. Profits are great. Please see the following for further reading. ​ A Study to Assess 18-Methoxycoronaridine https://www.clinicaltrials.gov/ct2/show/NCT04292197?lead=Mind+Medicine%2C+Inc.&lead_ex=Y&draw=2&rank=1 You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document. https://www.clinicaltrials.gov/ct2/history/NCT04292197?V_5=View#StudyPageTop Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence. They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website: Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality. No IND required Fast-tracked approvals Generous R&D refunds Excellent health system Access to patient databases Data accepted by FDA, EMA, CFDA & PDMA Looks like to me they will fast track in Australia - then partner with J&J if successful. What you read on this post is my understanding of this company. Do not invest based on this post. ----------------------------------------------------- tl/dr: Shrooms are the next Cannabis and meme stock. IPO on NASDAQ tomorrow.   submitted by   /u/InvestingWithGusto [link]   [comments]
    [visit article]
  42. WCG Clinical IPO: Here’s what you should know before investing in the stock (28/07/2021 - AlphaStreet)
    Of late, healthcare firms have been flocking to Wall Street, betting on the booming stock market to take business expansion to the next level. Currently going through a busy phase, the IPO market is probably headed for a record year. Among the most recent IPO aspirants, WCG Clinical Inc. has revealed plans to raise $720 million. 45 Mln Shares The Princeton, New Jersey-based provider of clinical trial solutions operates through the main business segments of Ethical Review and Clinical Trials Solutions. It is all set to offer around 45 million shares in the public market at a price between $15 and $17 per share. It is estimated that the company would value approximately $6.45 billion post-IPO. The proceeds will mainly be used for repaying debt. Read management/analysts’ comments on quarterly results After securing the SEC’s approval, the stock will start trading on the Nasdaq Global Select Market under the ticker symbol WCGC, tentatively in the first week of August 2021. It will be managed by a group of book-runners led by Goldman Sachs and Morgan Stanley. WCG was founded in 2012 and is supported by Singapore-based sovereign wealth fund GIC Private Limited. Since then, it has grown into a leading provider of advanced solutions for increasing the efficiency of clinical trials, by working closely with sponsors and contract research organizations. R&D Made Easy The disruption and delays caused by the COVID outbreak have prompted drug developers to employ technological solutions to support their clinical trial programs to overcome impediments and streamline the drug rollout process. WCG’s solutions are designed to help drug makers bring out new medicines in a time-bound and cost-effective manner. It is estimated that global biopharmaceutical research & development expenditures would reach $195 billion this year, while the return on investment is seen declining. The company’s specialized and integrated suite of technology applications and diversified client base, combined with its impressive track record, give it an edge over competitors. It has around 2,000 employees deployed across the world and more than 3,300 institutional and academic medical center practitioners. It is estimated that around 2.5 million patients have been enrolled in WCG-supported studies so far. Mixed 2020 In the fiscal year 2020, WCG generated revenues of $463.4 million, which is up 12% from the previous year. However, the bottom line was negatively impacted by a sharp increase in operating costs and the company slipped to a loss of $95.3 million from a profit of $18.2 million in fiscal 2019. Here’s all you need to know about Absci’s Nasdaq listing Despite being IPO-bound, WCG recently acquired VeraSci that offers eClinical software to support clinical trials for central nervous system disorders, as part of its efforts to boost scientific and patient engagement capabilities. The buyout is the latest in a series of deals, including the purchase of trial site communication solutions provider Trifecta, consultancy firm Waife & Associates, and patient recruitment specialist PharmaSeek.The post WCG Clinical IPO: Here’s what you should know before investing in the stock first appeared on AlphaStreet.
    [visit article]
  43. Taking a look at $DNLI today (29/04/2021 - Reddit Stocks)
    $DNLI: Returner from yesterday as I think this breakout still looks strong. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Elongated falling wedge breakout similar to that of OSTK on its first big run last winter. Multi-month breakout.   submitted by   /u/someoneUnreadable [link]   [comments]
    [visit article]
  44. Innovation Pharmaceuticals announcement ahead of phase II results for Brilacidin against COVID-19 in moderate to severe patients. (15/08/2021 - Reddit Stocks)
    http://www.ipharminc.com/press-release/2021/8/12/last-patient-last-visit-completed-in-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19-trial-database-undergoing-review-in-preparation-for-database-lock[Innovation Pharmaceuticals latest PR](http://www.ipharminc.com/press-release/2021/8/12/last-patient-last-visit-completed-in-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19-trial-database-undergoing-review-in-preparation-for-database-lock)   submitted by   /u/Ultimateeffthecrooks [link]   [comments]
    [visit article]
  45. Oncotelic closes COVID-19 clinical trial early (15/06/2021 - Seeking Alpha)

    [visit article]
  46. Cyclerion updates on clinical trial progress at webinar (28/04/2021 - Seeking Alpha)

    [visit article]
  47. Aptose Biosciences updates on clinical trial progress (24/03/2021 - Seeking Alpha)

    [visit article]
  48. Ra Medical provides enrollment update for atherectomy clinical trial (20/04/2021 - Seeking Alpha)

    [visit article]
  49. Recro expands capabilities for clinical trial services offerings (02/06/2021 - Seeking Alpha)

    [visit article]

For more information mailto [email protected]. Disclaimer.